• we cover more than 1,000 news per day, in 2 languages, and 83,000 stocks
Light Dark
it
italian it
english en

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

www.businesswire.com 19-12-2024 11:00 0.5 Minutes reading
NEW YORK--(BUSINESS WIRE)--COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic testing data to accelerate the development of new cancer therapies. Using the extensiv

Info

Related news
INARI MEDICAL INVESTOR ALERT by the Former Attorne...
07.01.25 11:55
by businesswire.com

INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn S...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, Inc. (NasdaqGS: NARI) to Stryker (NYSE: SYK). Under the terms of the proposed transaction, shareholders of Inari will receive $80.00 in cash for each share of Inari that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the c

Sentiment
0.46
Bearish/Bullish
50